Clinical trials: Glial Tumors
Glioma
Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents
- Trial name
- NCT00147160
- Testing
- Temozolomide, Cisplatinum
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 87 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreatic Cancer, Breast Cancer
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
Here's a polished version of the text: "This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian…
- Conditions
- Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT07651020
- Testing
- Specific SPECT imaging agents targeting LRRC15
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cytomegalovirus Positive, Glioblastoma
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with…
- Conditions
- Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma
- Trial name
- NCT02661282
- Testing
- Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme, Angiogenesis
Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months.
- Trial name
- NCT03225963
- Testing
- Chemoradiation with temozolomide
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taichung Veterans General Hospital
Glioblastoma
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
- Trial name
- NCT07093814
- Testing
- VRT106
- Where
- 11 sites in China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
DIPG
A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma
In this study, the investigators are testing improvement in survival outcomes in DIPG patients when stratified with MR perfusion score and treated with the said protocol.
- Trial name
- LoBULarDIPG (NCT04250064)
- Testing
- Bevacizumab Injection, Ultra-low-dose RT
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Tata Memorial Centre
Brain Tumor, Medulloblastoma
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma
There are two types of external radiation treatments (proton beam and photon beam). As part of the participant's treatment, they will receive radiation to the entire central nervous system (CNS); this is known as craniospinal…
- Conditions
- Brain Tumor, Medulloblastoma, Pineoblastoma
- Trial name
- NCT01063114
- Testing
- proton beam radiation
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Glioma, Malignant
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Glioma is a common brain tumor with a high risk of venous thromboembolism during treatment, especially in the months after surgery.
- Trial name
- NCT06196918
- Testing
- Rivaroxaban 10 MG
- Where
- 8 sites in China
- Volunteers
- 320 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Doctors and other medical scientists want learn about the biology of DIPG/DMG and to develop better ways to diagnose and treat patients with DIPG/DMG.
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma
- Trial name
- NCT03101813
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glioblastoma
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
The purpose of this study is to explore the safety profile and establish a recommended dose (RD) for phase II of the antibody-cytokine fusion protein L19TNF plus standard TMZ chemoradiotherapy in patients with newly diagnosed…
- Trial name
- GLIOSUN (NCT04443010)
- Testing
- Onfekafusp alfa, Temozolomide
- Where
- Switzerland
- Volunteers
- 226 people
- Sponsor
- Philogen S.p.A.
Glioblastoma, Astrocytoma, Grade IV
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Glioblastomas (GBM) are the most common type of primary brain tumors with an annual incidence of approximately 500 patients in the Netherlands.
- Trial name
- NCT02432417
- Testing
- Chloroquine
- Sponsor
- Maastricht Radiation Oncology
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma
- Trial name
- NCT00112736
- Testing
- erlotinib, temsirolimus, therapeutic conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Glioma
A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
This study is a prospective, single-arm clinical trial aimed at evaluating the safety and efficacy of ivoximab combined with temozolomide in the treatment of relapsed/refractory glioma.
- Trial name
- NCT07599371
- Testing
- Ivoximab 20 mg/kg, ivgtt, Q4W, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Recurrent Medulloblastoma, Recurrent Ependymoma
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma.
- Trial name
- NCT04743661
- Testing
- Irinotecan, Temozolomide, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pediatric Brain Tumor Consortium
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma.
- Trial name
- NCT03528642
- Testing
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Low Grade Glioma
Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
Low-grade glioma (LGG) represent typically slowly growing primary brain tumors with world health organization (WHO) grade I or II who affect young adults around their fourth decade.
- Trial name
- INDIGO (NCT05964569)
- Testing
- model-guided optimization of treatment plan, standard treatment plan, no optimization
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital Heidelberg
Brain and Central Nervous System Tumors
CC-5013 in Treating Patients With Recurrent Glioma
RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
- Trial name
- NCT00036894
- Testing
- lenalidomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, mannitol, and sodium thiosulfate, and to see how well they work in treating patients with central nervous system…
- Conditions
- Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma
- Trial name
- NCT00983398
- Testing
- Carboplatin, Mannitol, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.